Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPID: Quetiapine IR Titration in Acute Schizophrenia
NCT00457899Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of quetiapine (extended-release tablet, brand name: Bipresso) in schizophrenia and schizoaffective disorder (2 arms), sponsored by AstraZeneca. Primary endpoint: Positive and Negative Syndrome Scale Total Score at Day 7. Started Jul 2007; status: terminated.
02
Drugs
quetiapine (extended-release tablet, brand name: Bipresso)
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00457899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00457899.